Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Tóm tắt
Từ khóa
Tài liệu tham khảo
Weissenbach J, Chernajovsky Y, Zeevi M, et al. 1980. Two interferon mRNA in human fibroblasts:in vitrotranslation andEscherichia colicloning studies.Proc. Natl. Acad. Sci. USA77:7152–56
Sehgal PB, Greininger G, Tosato G. 1989. Acute phase and immune responses: interleukin-6.Ann. NY Acad. Sci.557:1–583
Hirano T, Teranishi T, Lin BH, Onoue K. 1984. Human helper T cell factor(s). IV. Demonstration of a human late-acting B cell differentiation factor acting onStaphylococcus aureusCowen I-stimulated B cells.J. Immunol.133:798–802
Muraguchi A, Hirano T, Tang B, et al. 1988. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.J. Exp. Med.67:332–44
Takatsuki F, Okano A, Suzuki C, et al. 1988. Human recombinant IL-6/B cellstimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo.J. Immunol.141:3072– 77
1988, J. Exp. Med., 167, 1414
Okada M, Kitahara N, Kishimoto S, et al. 1988. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.J. Immunol.141:1543– 49
Renauld JC, Vink A, Van Snick J. 1989. IL1 and IL6 in CTL induction-accessory signals in murine cytolytic T cell responses: dual requirement for IL1 and IL6.J. Immunol.143:1894–98
Passeri G, Girasole G, Markus T, et al. 1991. 17B-estradiol regulates IL-6 production and osteoclast development in murine calvaria cell cultures.J. Bone Miner. Res.6:S263 (Suppl. 1)
Girasole G, Jilka RL, Passeri G, et al. 1992. 17β-estradiol inhibits interleukin6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.J. Clin. Invest.89(3):883–91
Jilka RL, Hangoc C, Girasole G, et al. 1992. Increased osteoclast development after estrogen loss: mediation by interleukin-6.Science257:88–91
Miyaura C, Kusano K, Masuzawa T, et al. 1995. Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6.J. Bone Miner. Res.10:1365–73
Poli V, Balena R, Fattori E, et al. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.EMBOJ.13:1189–96
1995, Mol. Hum. Reprod., 1, 2793
Tabibzadeh SS, Santhanam U, Sehgal PB, May LT. 1989. Cytokine-induced production of IFN-β2/IL-6 by freshly explanted human endometrial stromal cells. Modulation by estradiol-17β.J. Immunol.142(9):3134–39
Krueger JG, Krane JF, Carter DM, Gottlieb AB. 1990. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis.J. Invest. Dermatol.94:135–140 (Suppl.)
Navarro S, Devili N, LeCouedic JP, et al. 1991. Interleukin-6 and its receptor are expressed by human megakaryocytes:in vitroeffects on proliferation and endoreplication.Blood77:461–71
Sun WH, Binkley N, Bidwell DW, Ershler WB. 1993. The influence of recombinant human interleukin-6 on blood and immune parameters in middleaged and old rhesus monkeys.Lymphokine Cytokine Res.12(6):449–55
Yasukawa K, Hirano T, Watanabe Y, et al. 1987. Structure and expression of human B cell stimulatory factor-2 (BSF2/IL-6) gene.EMBO J.6(10):2939–45
Simpson RJ, Moritz RL, Rubira MR, Van Snick J. 1988. Murine hybridoma/ plasmacytoma growth factor: complete amino acid sequence and relation to human interleukin-6.Eur. J. Biochem.176:187–97
Zhang Y, Lin J-X, Vilcek J. 1988. Synthesis of interleukin-6 (interferon-β2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP.J. Biol. Chem.263:6177–82
Zhang Y, Lin J-X, Yip YK, Vilcek J. 1988. Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin-1 in human fibroblasts: role in the induction of interleukin-6.Proc. Natl. Acad. Sci. USA85:6802–6
Zhang Y, Broser M, Rom WN. 1994. Activation of the interleukin 6 gene byMycobacterium tuberculosisor lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B.Proc. Natl. Acad. Sci USA91(6):2225–29
Yamashita I, Katamine S, Moriuchi R, et al. 1994. Transactivation of the human interleukin-6 gene by human T-lymphotropic virus type 1 Tax protein.Blood84(5):1573–78
Yan SF, Tritto I, Pinsky D, et al. 1995. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6.J. Biol. Chem.270(19):11463–71
Dendorfer U, Oettgen P, Libermann TA. 1994. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide.Mol. Cell. Biol.14(7):4443–54
Scala G, Ruocco MR, Ambrosino C, et al. 1994. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein.J. Exp. Med.179(3):961–71
Brach MA, Gruss HJ, Kaisho T, et al. 1993. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kappa B.J. Biol. Chem.268(12):8466–72
Margulies L, Sehgal PB. 1993. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPβ (NF-IL6) activity by p534 species.J. Biol. Chem.268:15096–100
Janaswami PM, Kalvakolanu DV, Zhang Y, Sen GC. 1992. Transcriptional repression of interleukin-6 gene by adenoviral E1A proteins.J. Biol. Chem.267(34):24886–91
Brach MA, de Vos S, Arnold C, et al. 1992. Leukotriene B4 transcriptionally activates interleukin-6 expression involving NK-chi B and NF-IL6.Eur. J. Immunol.22(10):2705–11
Gruss HJ, Brach MA, Herrmann F. 1992. Involvement of nuclear factor-kappa B in induction of the interleukin-6 gene by leukemia inhibitory factor.Blood80(10):2563–70
Tanabe O, Akira S, Kamiya T, et al. 1988. Genomic structure of the murine IL-6 gene: high degree of conservation of potential regulatory sequences between mouse and human.J. Immunol.141:3875–81
Ray A, LaForge KS, Sehgal PB. 1990. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion.Mol. Cell. Biol.10:5736–46
Ray A, LaForge KS, Sehgal PB. 1991. Repressor to activator switch by mutations in the glucocorticoid receptor: Is direct DNA binding necessary?Proc. Natl. Acad. Sci. USA88(16):7086–90
Ray A, Prefontaine KE. 1994. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor.Proc. Natl. Acad. Sci. USA91(2):752–56
Deleted in proof
Auphan N, DiDonato A, Rosette C, 1995. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis.Science270:286–290
Navarra P, Tsagarakis S, Faria M, et al. 1990. Interleukin-1 and -6 stimulate the release of corticotropin-releasing hormone from rat hypothalamusin vitrovia eicosanoid cyclooxygenase pathway.Endocrinology128:37–44
Lyson K, Milenkovic K, McCann SM. 1991. The stimulatory effect of interleukin-6 on corticotropin-releasing factor and thyrotropin-releasing hormone secretionin vitro.Prog. Neuroendocrinol. Immunol.4:161–65
1989, Am. J. Pathol., 135, 427
Kania DM, Binkley N, Checovich M, et al. 1995. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density.J. Am. Geriatr. Soc.43(3):236–39
Ralston SH. 1994. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis.J. Bone Miner. Res.9:883–90
Daynes RA, Araneo BA, Ershler WB, et al. 1993. A dysregulation in the production of interleukin-6 with normal aging: probable linkage to the age associated depression in dehydroepiandrosterone (DHEA) and its sulfated derivative.J. Immunol.150:5219–30
Chaudhary LR, Spelsberg TC, Riggs BL. 1992. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1β and tumor necrosis factor-α: lack of regulation by 17β-estradiol.Endocrinology130:2528– 34
Rifas L, Kenney JS, Marcelli M, et al. 1995. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: evidence that induction by interleukin-1 and tumor necrosis factor-a is not regulated by ovarian steroids.Endocrinology136:4056–67
Pottratz ST, Bellido T, Mocharla H, et al. 1994. 17β-Estradiol inhibits expression of human promoter-reporter constructs by a receptor-dependent mechanism.J. Clin. Invest.93(3):944–50
Ray A, Prefontaine KE, Ray P. 1994. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor.J. Biol. Chem.269(17):12940–46
Deleted in proof
Stein B, Yang MX. 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/ EBPβ.Mol. Cell. Biol.15(9):4971–79
Bellido T, Jilka RL, Boyce BF, et al. 1995. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor.J. Clin. Inv.95(6):2886–95
Yamasaki K, Taga T, Hirata Y, et al. 1988. Cloning and expression of the human interleukin-6 (BSF-2/IFNβ 2) receptor.Science241:825–28
1993, Hum. Genet., 90, 542
Bazan JF. 1989. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chain.Biochem. Biophys. Res. Commun.164:788–95
Taga T, Hibi M, Murakami M, et al. 1992. Interleukin-6 receptor and signals.Chem. Immunol.1992; 51:181–204
Murakami M, Hibi M, Nakagawa N, et al. 1993. IL-6-induced homodimerization of gp 130 and associated activation of a tyrosine kinase.Science260:1808– 10
Lust JA, Jelinek DF, Donovan KA, et al. 1994. Sequence, expression and function of an mRNA encoding of the human interleukin-6 receptor (sIL-6R).Curr. Top. Microbiol. Immunol.194:199–205
Nakajima T, Yamamoto S, Cheng M, et al. 1992. Soluble interleukin-6 receptor is released from receptor-bearing cell linein vitro.Jpn. J. Cancer Res.83:373– 78
Tang B, Matsuda T, Akira S, et al. 1991. Age-associated increase in interleukin 6 in MRL/lpr mice.Int. Immunol.3(3):273–78
Suzuki H, Yasukawa K, Saito T, et al. 1993. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal.Eur. J. Immunol.23(5):1078–82
Effros RB, Svoboda K, Walford RL. 1993. Influence of age and caloric restriction on macrophage IL-6 and TNF production.Lymphokine Cytokine Res.10(5):347–51
Zhou D, Chrest FJ, Adler W, et al. 1993. Increased production of TGF-beta and IL-6 by aged spleen cells.Immunol. Lett.36(1):7–11
1992, Am. J. Physiol., 262, R211
Ershler WB, Sun WH, Binkley N, et al. 1993. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction.Lymphokine Cytokine Res.12(4):225–30
Sindermann J, Kruse A, Frercks HJ, et al. 1993. Investigations of the lymphokine system in elderly individuals.Mech. Ageing Dev.70(1–2):149–59
McKane R, Khosla S, Peterson J. 1993. Effect of age and menopause on serum interleukin-6 levels in women.J. Bone Miner. Res.8:S157 (Suppl.)
Fagiolo U, Cossarizza A, Scala E, et al. 1993. Increased cytokine production in mononuclear cells of healthy elderly people.Eur. J. Immunol.23(9):2375–78
1993, Aging Immunol. Infect. Dis., 4, 139
Klein B, Zhang X, Jourdan M, et al. 1989. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.Blood73(2):517–26
Kato H, Kinoshita T, Suzuki S, et al. 1996. Elevated serum interleukin-6 (IL6) is derived from neoplastic lymphoid cells in patients with B-cell non-Hodgkin’s lymphoma: correlation with extent of IL-6 expression and serum concentration.Br. J. Haematol.92(4):1014–21
1993, Cancer Res., 53, 2118
Lavabre-Bertrand T, Exbrayat C, Liautard J, et al. 1995. Detection of membrane and soluble interleukin-6 receptor, in lymphoid malignancies.Br. J. Haemaol.91(4):871–77
Yoshizaki K, Matsuda T, Nishimoto N, et al. 1989. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease.Blood74:1360–67
Gause A, Scholz R, Klein S, et al. 1991. Increased levels of circulating interleukin-6 in patients with Hodgkin’s disease.Hematol. Oncol.9(6):307–13
Yamamura M, Honda M, Yamada Y, et al. 1996. Increased levels of interleukin6 (IL-6) in serum and spontaneous in vitro production of IL-6 by lymph node mononuclear cells of patients with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) and clinical effectiveness of cyclosporin A.Leukemia10(9):1504–8
Kim SS, Chung SM, Choi IP, Byun KH. 1995. Expression of interleukin-6 in polymorphic reticulosis—immunohistochemical study.J. Korean Med. Sci.10(5):324–28
Stasi R, Zinzani L, Galieni P, et al. 1995. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive nonHodgkin’s lymphoma.Eur. J. Haematol.54(1):9–17
Seymour JF, Talpaz M, Cabanillas F, et al. 1995. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.J. Clin. Oncol.13(3):575–82
Kanno H, Yasunaga Y, Iuchi K, et al. 1996. Interleukin-6 mediated growth enhancement of cell lines derived from pyothorax-associated lymphoma.Lab. Invest.75(2):167–73
Yee C, Biondi A, Wang XH, et al. 1989. A possible autocrine role for interleukin6 in two lymphoma cell lines.Blood74(2):798–804
Takeshita M, Sumiyoshi Y, Masuda, Y, et al. 1993. Cytokine (interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6)-possessing cells in lymph nodes of malignant lymphoma.Pathol. Res. Pract.189(1):18–25
Voorzanger N, Touitou R, Garcia E, et al. 1996. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors.Cancer Res.56(23):5499–505
1993, Cancer Res., 54, 3054
Weindruch R, Walford RL. 1988.The Retardation of Aging and Disease by Dietary Restriction.Springfield, IL: Thomas
Peled A, Tzehoval E, Haran-Ghera N. 1995. Role of cytokines in termination of the B cell lymphoma dormant state in AKR mice.Leukemia9(6):1095–101
Hilbert DM, Kopf M, Mock BA, et al. 1995. Interleukin-6 is essential for in vivo development of B lineage neoplasms.J. Exp. Med.182(1):243–48
Gaillard JP, Bataille R, Brailly H, et al. 1993. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.Eur. J. Immunol.23:820– 24
Bataille R, Jourdan M, Zhang XG, Klein B. 1989. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias.J. Clin. Invest.84:2008– 11
Stauder R, Van Driel M, Schwarzler C, et al. 1996. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma.Blood88(8):3101–8
1992, Curr. Top. Microbiol. Immunol., 182, 237
Klein B, Lu ZY, Bataille R. 1992. Clinical applications of IL6 inhibitors.Res. Immunol.143(7):774–76
1991, Blood, 5, 1198
Manolagas SC, Jilka RL. 1995. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.N. Engl. J. Med.332(5):305–11
1991, Crit. Rev. Immunol., 11, 195
Bellido T, Girasole G, Passeri G, et al. 1994. Sex steroids regulate the expression of the gp130 transduction pathway by bone marrow and bone cells.Bone Miner.25(S1):S39
Taguchi Y, Yamate T, Mocharia H, et al. 1996. Interleukin-6 induces osteoblast differentiation in uncommitted embryonic fibroblasts (EF).J. Bone Miner. Res.11:S101 (Suppl.) (Abstr.)
Löwik CWGM, van der Pluijm G, Bloys H, et al. 1989. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis.Biochem. Biophys. Res. Commun.162:1546–52
Rahman S, Bunning RAD, Dobson PRM, et al. 1992. Bradykinin stimulates the production of prostaglandin E2 and interleukin-6 in human osteoblast-like cells.Biochim. Biophys. Acta1135:97– 102
Flanagan AM, Stow MD, Williams R. 1995. The effect of interleukin-6 and soluble interleukin-6 receptor protein on the bone resorptive activity of human osteoclasts generatedin vitro.J. Pathol.176:289–97
Roodman GD, Kurihara N, Ohsaki Y, et al. 1992. Interleukin-6: a potential autocrine/paracrine factor in Paget’s disease of bone.J. Clin. Invest.89:46–52
Black KS, Mundy GR, Garrett IR. 1991. Interleukin-6 causes hypercalcemia in vivo, and enhances the bone resorbing potency of interleukin-1 and tumor necrosis factor by two orders of magnitude in vitro.J. Bone Miner. Res.6:S271 (Suppl.)
Bauer J, Ganter U, Strauss S, et al. 1992. The participation of interleukin-6 in the pathogenesis of Alzheimer’s disease.Res. Immunol.143(6):650–57
Vandenabelle P, Fiers W. 1991. Is amyloidogenesis during Alzheimer’s disease due to an IL-1/IL-6-mediated “acute phase response” in the brain?Immunol. Today12:217–19
Ganter U, Strauss S, Jonas V, et al. 1991. Alpha-2 macroglobulin synthesis in interleukin-6 stimulated human neuronal (SH-SY5Y neuroblastoma) cells.FEBS Lett.282:127–31
1992, Lab. Invest., 66, 223
Wood JA, Wood PL, Ryan R, et al. 1993. Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2macroglobulin and C-reactive protein.Brain Res.629(2):245–52
Blum-Degen D, Muller T, Kuhn W, et al. 1995. Interleukin-1 beta and interleukin6 are elevated in the cerebrospinal fluid of Alzheimer’s disease and de novo Parkinson’s disease patients.Neurosci. Lett.202(1–2):17–20
Yamada K, Kono K, Umegaki H, et al. 1995. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia.Neurosci. Lett.186(2–3):219–21
Chao CC, Ala TA, Hu S, et al. 1994. Serum cytokine levels in patients with Alzheimer’s disease.Clin. Diagn. Lab. Immunol.1(4):433–36
van Duijn CM, Hofman A, Nagelkerken L. 1990. Serum levels of interleukin-6 are not elevated in patients with Alzheimer’s disease.Neurosci. Lett.108:350– 54
Cadman ED, Witte DG, Lee CM. 1994. Regulation of the release of interleukin6 from human astrocytoma cells.J. Neurochem.63(3):980–87
Del Bo R, Angeretti N, Lucca E, et al. 1995. Reciprocal control of inflammatory cytokines, IL-1, IL-6 and beta-amyloid production in cultures.Neurosci. Lett.188(1):70–74
Hull M, Strauss S, Berger M, et al. 1996. The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer’s disease.Behav. Brain Res.78(1):37–41
Huell M, Strauss S, Volk B, et al. 1995. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer’s disease patients.Acta Neuropathol.89(6):544–51
Cacabelos R, Franco-Maside A, Alvarez XA. 1991. Interleukin 1 in Alzheimer’s disease and multi-infarct dementia: neurophysiological correlations.Methods Exp. Clin. Pharmacol.13:703–8
Huberman M, Sredni B, Stern L, et al. 1995. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease.J. Neurol. Sci.130(2):161–64
Shalit F, Sredni B, Stern L, et al. 1994. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer’s patients.Neurosci. Lett.174(2):130–32
Fattori E, Lazzaro D, Musiani P, et al. 1995. IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage.Eur. J. Neurosci.7(12):2441–49
Bellinger FP, Madamba SG, Campbell IL, Siggins GR. 1995. Reduced long term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6.Neurosci. Lett.198(2):95–98
Brett FM, Mizisin AP, Powell HC, Campbell IL. 1995. Evolution of neuropathologic abnormalities associated with blood brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes.J. Neuropathol. Exp. Neurol.54(6):766–75
Chiang CS, Stalder A, Samimi A, Campbell IL. 1994. Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice.Dev. Neurosci.16(3–4):212–21
Steffensen SC, Campbell IL, Henriksen SJ. 1994. Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice.Brain Res.652(1):149–53
Campbell IL, Abraham CR, Masilaah E, et al. 1993. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6.Proc. Natl. Acad. Sci. USA90(21):10061–65
Kawas C, Resnick S, Morrison A, et al. 1997. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging.Neurology48(6):1517–21
Stewart WF, Kawas C, Corrada M, Metter EJ. 1997. Risk of Alzheimer’s disease and duration of NSAID use.Neurology48(3):626–32
1994, Lymphokine Cytokine Res., 13, 221